Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Estrella ImmunopharmaESLA -1.11%12 EV-to-FCF is -3.33 as of Aug. 28, 2026. GuruFocus rates ESLA with a GF Score™ of 12/100. The stock has 1 warning sign investors should review. Among 321 Biotechnology companies, Estrella Immunopharma ranks worse than 311526.17% on this metric.
EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, Estrella Immunopharma's Enterprise Value is $31.26 Mil.
Estrella Immunopharma's Free Cash Flow for the trailing twelve months (TTM) ended in Jun. 2026 was $-9.38 Mil. Therefore, Estrella Immunopharma's EV-to-FCF for today is -3.33.
The historical rank and industry rank for Estrella Immunopharma's EV-to-FCF or its related term are showing as below:
ESLA'
s EV-to-FCF Range Over the Past 10 Years
Min: -3.46 Med: 0 Max: 0
Current: -3.33
ESLA's EV-to-FCF is ranked worse than 100% of 321
companies
in the Biotechnology industry
Industry Median: 18.01
vs ESLA: -3.33
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Estrella Immunopharma's PE Ratio (TTM) for today is calculated as:
Estrella Immunopharma's share price for today is $0.7072.
Estrella Immunopharma's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.240.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Estrella Immunopharma's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Estrella Immunopharma EV-to-FCF vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Estrella Immunopharma's EV-to-FCF distribution charts can be found below:
* The bar in red indicates where Estrella Immunopharma's EV-to-FCF falls into.
Estrella Immunopharma's current Enterprise Value is $31.26 Mil.
Estrella Immunopharma's Free Cash Flow for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-9.38 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Estrella Immunopharma (ESLA) has a EV-to-FCF of -3.33 as of Aug. 28, 2026. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Estrella Immunopharma and its competitors. According to the industry distribution chart, Estrella Immunopharma ranks #999999 out of 321 companies in the Biotechnology industry.
Is Estrella Immunopharma's EV-to-FCF too high?
Estrella Immunopharma's current EV-to-FCF is -3.33. Based on the distribution chart, Estrella Immunopharma ranks #999999 out of 321 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Estrella Immunopharma has a GF Score™ of 12/100, reflecting its overall financial health beyond just this single metric.
How does Estrella Immunopharma's EV-to-FCF compare to LITS and NNVC?
According to the Biotechnology industry distribution chart, Estrella Immunopharma ranks #999999 out of 321 companies for EV-to-FCF. This places Estrella Immunopharma in the lower half of its industry. The industry median EV-to-FCF is 18.01. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-FCF for a Biotechnology company?
The median EV-to-FCF among Biotechnology companies is 18.01, based on 321 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-FCF significantly above this median, while those in the bottom quartile fall well below. However, EV-to-FCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-FCF mean?
A high EV-to-FCF can signal that a stock is expensive relative to its fundamentals. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Estrella Immunopharma and its competitors. For the Biotechnology industry, the median EV-to-FCF is 18.01 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Estrella Immunopharma's current EV-to-FCF is -3.33. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Estrella Immunopharma stock overvalued right now?
Estrella Immunopharma (ESLA) has a current EV-to-FCF of -3.33. The current EV-to-FCF is -3.33. Estrella Immunopharma's overall GF Score™ is 12/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-FCF calculated?
EV-to-FCF is calculated from a company's financial statements. For Estrella Immunopharma (ESLA), the current EV-to-FCF is -3.33 as of Aug. 28, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Estrella Immunopharma Inc is a clinical-stage biopharmaceutical company. The company is engaged in developing CD19 and CD22-targeted ARTEMIS T-cell therapies with the capacity to address treatment challenges for patients with blood cancers and solid tumors.
12GF Score
Get the complete analysis for ESLA
EV-to-FCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ESLA has been successfully added to your 
